Methodology, biology and clinical applications of human mesenchymal stem cells.
Camassola M., de Macedo Braga LM., Chagastelles PC., Nardi NB.
Clinical Trial on Immune Modulation, Autoimmune Research, published in Methods Mol Biol (2012) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Methods Mol Biol (2012)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 22610579
- DOI
- 10.1007/978-1-61779-815-3_30
Abstract (original English)
Stem cells are known by their capacity of self-renewal and differentiation into at least one specialized cell type. Mesenchymal stem cells (MSCs) were isolated initially from bone marrow but are now known to exist in any vascularized organ or tissue in adults. MSCs have a great therapeutic potential, due to their ability to migrate to sites of tissue injury and secrete trophic factors that hasten endogenous repair. They have also been shown to present immunosuppressive properties that may be used in the treatment of autoimmune or graft-versus-host diseases. Clinical trials employing MSCs show that the therapy is safe, but the efficiency needs to be in tested in phase III and IV studies. We describe here protocols for the isolation of human MSCs from human bone marrow and adipose tissue. The safe use of these cells demand a thorough in vitro characterization, as described in protocols of immunophenotyping by flow cytometry and analysis of their capacity to differentiate into adipogenic, osteogenic, and chondrogenic lineages.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries.
Systematic Review on Skin Aging, Immune Modulation, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.
- 2026
J Cosmet Dermatol - Level ASystematic ReviewEurope PMC
Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review
Systematic Review on Immune Modulation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Stromal Vascular Fraction in Bone Healing: A Systematic Review of Clinical Evidence and Potential Implications in Skull Base Reconstruction and Cranioplasty.
Systematic Review with a reported sample of 214 on Chronic Wound, Immune Modulation, published in J Craniofac Surg (2026) — summary generated from the PubMed abstract.
- 2026
- n = 214
J Craniofac Surg - Level AMeta-analysisEurope PMC
The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials
Meta-analysis on Immune Modulation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Res Ther - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol